Eli Lilly (NYSE:LLY) is said to be working on a potential €15 billion offer to acquire French biotechnology company Abivax (NASDAQ:ABVX), according to a report published on Monday by La Lettre.

The U.S. pharmaceutical group has not yet formally approached Abivax’s board, but remains interested in the transaction, the report said.

Before launching an official bid, Eli Lilly is reportedly seeking guidance from the French Finance Ministry on whether the proposed acquisition would be subject to France’s foreign investment control framework.

If it proceeds, the deal would represent a significant strategic move for Eli Lilly, strengthening its presence in the French biotechnology market.

Eli Lilly stock price

Join the discussion: Connect with other investors on your favorite stocks or explore the top-talked-about stocks on our Breakout Boards.

This article was written by the editorial team at InvestorsHub/ADVFN and is provided for informational purposes only. In some cases, editorial staff may use artificial intelligence–based tools to assist in the research, drafting, or editing of content, under human review and oversight. This article does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. The views expressed are based on publicly available information believed to be reliable at the time of publication, but accuracy or completeness is not guaranteed. Readers should conduct their own independent research and consult a qualified financial professional before making any investment decisions.